^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    ITK inhibitor

    Related drugs:
    1m
    Phosphoproteomic analysis of successive Jurkat CD19-CAR generations reveals TCRζ-driven signalling. (PubMed, Cell Signal)
    Finally, we found that selective, partial inhibition of Itk using Soquelitinib reduced basal CD69 expression in CAR-Jurkat cells while maintaining their ability to activate in response to antigen. These data suggest that TCRζ determines the pY signalling profile and that Itk drives basal activation of CD19-CAR Jurkats, which may impact evaluation of new CAR designs in CAR-Jurkat screens.
    Journal • IO biomarker
    |
    CD47 (CD47 Molecule) • CD69 (CD69 Molecule) • PTPN22 (Protein Tyrosine Phosphatase Non-Receptor Type 22)
    |
    soquelitinib (CPI-818)
    1m
    Safety, tolerability, and preliminary efficacy of CPI-818 in the treatment of moderate to severe atopic dermatitis (ChiCTR2500110450)
    P1/2, N=123, Not yet recruiting, Shanghai Skin Disease Hospital; Angel Pharmaceutical
    New P1/2 trial
    |
    soquelitinib (CPI-818)
    5ms
    Inclusion of the ζ-chain drives phosphotyrosine signalling in CD19-CAR T cells. (PubMed, bioRxiv)
    Finally, we find that selective, partial inhibition of Itk using Soquelitinib reduces basal CD69 expression in Jurkat CAR T cells while maintaining their ability to activate in response to antigen. Our data suggest that the ζ-chain determines the pY signalling profile of CD19-CAR Jurkat T cells and that Itk may drive antigen-independent CD19-CAR activation.
    Journal
    |
    CD69 (CD69 Molecule) • PTPN22 (Protein Tyrosine Phosphatase Non-Receptor Type 22)
    |
    soquelitinib (CPI-818)
    6ms
    Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD (clinicaltrials.gov)
    P1, N=72, Recruiting, Corvus Pharmaceuticals, Inc. | Trial completion date: Apr 2025 --> Nov 2025 | Trial primary completion date: Apr 2025 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    soquelitinib (CPI-818)
    7ms
    Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov)
    P2, N=14, Completed, Aclaris Therapeutics, Inc. | Active, not recruiting --> Completed
    Trial completion
    8ms
    Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma (clinicaltrials.gov)
    P3, N=150, Recruiting, Corvus Pharmaceuticals, Inc. | Trial completion date: Sep 2027 --> Jul 2028 | Trial primary completion date: Feb 2026 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    Beleodaq (belinostat) • Folotyn (pralatrexate) • soquelitinib (CPI-818)
    9ms
    Study of ATI-2138 in Adult Participants with Moderate to Severe Atopic Dermatitis (clinicaltrials.gov)
    P2, N=14, Active, not recruiting, Aclaris Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    10ms
    Therapeutic Targeting of Interleukin-2-Inducible T-Cell Kinase (ITK) for Cancer and Immunological Disorders: Potential Next-Generation ITK Inhibitors. (PubMed, OMICS)
    This specificity and optimization hold potential for the development of next-generation ITK inhibitors with possible applications in the treatment of immune-related disorders and cancers. Further in vitro, in vivo, and translational clinical research are called for.
    Journal
    |
    IL2 (Interleukin 2) • ITK (IL2 Inducible T Cell Kinase)
    12ms
    Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients (clinicaltrials.gov)
    P2, N=14, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID)
    New P2 trial
    |
    soquelitinib (CPI-818)
    1year
    IL-2-inducible T cell kinase deficiency sustains chimeric antigen receptor T cell therapy against tumor cells. (PubMed, J Clin Invest)
    Moreover, ITK-deficient CD19-CAR-T cells showed better control of tumor relapse. Our work provides a promising strategy of targeting ITK to develop sustainable CAR-T products for clinical use.
    Journal • CAR T-Cell Therapy • IO biomarker • Tumor cell
    |
    IL2 (Interleukin 2) • ITK (IL2 Inducible T Cell Kinase)
    1year
    The Safety, Tolerability, PK, and PD of DWP213388 After SAD and MAD Administration in Healthy Adult Subjects (clinicaltrials.gov)
    P1, N=0, Withdrawn, Daewoong Pharmaceutical Co. LTD. | N=72 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    1year
    Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma (clinicaltrials.gov)
    P3, N=150, Recruiting, Corvus Pharmaceuticals, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Beleodaq (belinostat) • Folotyn (pralatrexate) • soquelitinib (CPI-818)